Daniel V OHara
Overview
Explore the profile of Daniel V OHara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marsh S, Varghese A, Snead C, Hole B, OHara D, Agarwal N, et al.
Kidney Int Rep
. 2024 Jul;
9(7):2198-2208.
PMID: 39081736
Introduction: Kidney supportive care (KSC) integrates kidney and palliative care to improve quality of life for people with chronic kidney disease (CKD). Despite increasing interest and global advocacy to integrate...
2.
OHara D, Janse R, Fu E, Jardine M, Carrero J
Diabetes Res Clin Pract
. 2024 Jun;
213:111745.
PMID: 38876274
Aims: To assess adherence and persistence to sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1-RA), and dipeptidyl peptidase-4 inhibitors (DPP4i) in routine care. Methods: Using retrospective healthcare data from...
3.
OHara D, Lam C, McMurray J, Yi T, Hocking S, Dawson J, et al.
Nat Rev Nephrol
. 2024 Apr;
20(8):513-529.
PMID: 38671190
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes mellitus (T2DM). In the past...
4.
Yi T, OHara D, Smyth B, Jardine M, Levin A, Morton R
Can J Kidney Health Dis
. 2024 Jan;
11:20543581231217857.
PMID: 38161391
Background: Care gaps remain in modern health care despite the availability of robust, evidence-based medications. Although sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated profound benefits in improving both cardiovascular and kidney...
5.
OHara D, Yi T, Lee V, Jardine M, Dawson J
Nephrology (Carlton)
. 2022 Sep;
27(12):917-924.
PMID: 36176176
Non-adherence to medications is a critical challenge in the management of people with chronic kidney disease (CKD). This review explores the complexities of adherence in this population, the unique barriers...
6.
7.
Worth H, OHara D, Agarwal N, Collister D, Brennan F, Smyth B
Clin J Am Soc Nephrol
. 2022 Jan;
17(6):911-921.
PMID: 34987023
People with kidney failure can experience a range of symptoms that lead to suffering and poor quality of life. Available therapies are limited, and evidence for new treatment options is...
8.
OHara D, Wong J, Cooper B, Wong G, Wong M, Cheikh Hassan H
J Nephrol
. 2021 Apr;
34(6):2131-2136.
PMID: 33856685
No abstract available.
9.
OHara D, Parkhill T, Badve S, Jun M, Jardine M, Perkovic V
Diabetes Obes Metab
. 2020 Dec;
23(3):763-773.
PMID: 33269512
Aims: To summarize evidence from randomized controlled trials (RCTs) concerning the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on kidney outcomes in patients with type 2 diabetes mellitus (T2DM). Methods: The...
10.
Puri P, Hanxhiu A, OHara D, Hsu D, Vucak-Dzumhur M
BMC Nephrol
. 2020 Nov;
21(1):488.
PMID: 33203373
Background: Pregnancy-related Atypical Haemolytic Uremic Syndrome (P-aHUS) is a rare condition affecting genetically predisposed women during pregnancy. It is often difficult to diagnose and has a significant impact on maternal...